{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:27:55Z","timestamp":1777433275077,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS073502"],"award-info":[{"award-number":["NS073502"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG008051"],"award-info":[{"award-number":["AG008051"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["IIRG-13-283707"],"award-info":[{"award-number":["IIRG-13-283707"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0337-3","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T12:09:14Z","timestamp":1517227754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Anti-\u03b2-sheet conformation monoclonal antibody reduces tau and A\u03b2 oligomer pathology in an Alzheimer\u2019s disease model"],"prefix":"10.1186","volume":"10","author":[{"given":"Fernando","family":"Go\u00f1i","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Mart\u00e1-Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal","family":"Herline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Peyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allal","family":"Boutajangout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Prelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","volume":"35","author":"JL Tomic","year":"2009","unstructured":"Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer\u2019s disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352\u20138.","journal-title":"Neurobiol Dis"},{"key":"337_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4161\/pri.23061","volume":"7","author":"KH Ashe","year":"2013","unstructured":"Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion. 2013;7:55\u20139.","journal-title":"Prion"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1212\/NXI.0000000000000237","volume":"3","author":"EM Knight","year":"2016","unstructured":"Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW. Effective anti-Alzheimer A\u03b2 therapy involves depletion of specific A\u03b2 oligomer subtypes. Neurol Neuroimmunol Neuroinflamm. 2016;3:e237.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"337_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"337_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.22615","volume":"70","author":"M Jucker","year":"2011","unstructured":"Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532\u201340.","journal-title":"Ann Neurol"},{"key":"337_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature20416","volume":"539","author":"R Riek","year":"2016","unstructured":"Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016;539:227\u201335.","journal-title":"Nature"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaneurol.2013.1453","volume":"70","author":"LC Walker","year":"2013","unstructured":"Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013;70:304\u201310.","journal-title":"JAMA Neurol"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-017-0293-3","volume":"9","author":"DL Brody","year":"2017","unstructured":"Brody DL, Jiang H, Wildburger N, Esparza TJ. Non-canonical soluble amyloid-\u03b2 aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9:62.","journal-title":"Alzheimers Res Ther"},{"key":"337_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet"},{"key":"337_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns N, Davies P, Tredici KD, Duyckaerts C, Frosch MP, Hof PR, Hulette C, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee A, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer\u2019s disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"337_CR11","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","volume":"85","author":"T Wisniewski","year":"2015","unstructured":"Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer\u2019s disease. Neuron. 2015;85:1162\u201376.","journal-title":"Neuron"},{"key":"337_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/14760584.2016.1121815","volume":"15","author":"T Wisniewski","year":"2016","unstructured":"Wisniewski T, Drummond E. Developing therapeutic vaccines against Alzheimer\u2019s disease. Expert Rev Vaccines. 2016;15:401\u201315.","journal-title":"Expert Rev Vaccines"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11481-015-9637-6","volume":"11","author":"SK Schroeder","year":"2016","unstructured":"Schroeder SK, Joly-Amado A, Gordon MN, Morgan D. Tau-directed immunotherapy: a promising strategy for treating Alzheimer\u2019s disease and other tauopathies. J Neuroimmune Pharmacol. 2016;11:9\u201325.","journal-title":"J Neuroimmune Pharmacol"},{"key":"337_CR14","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.2174\/1381612822666160518142226","volume":"22","author":"J Gerson","year":"2016","unstructured":"Gerson J, Kayed R. Therapeutic approaches targeting pathological tau aggregates. Curr Pharm Des. 2016;22:4028\u201339.","journal-title":"Curr Pharm Des"},{"key":"337_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","volume":"9","author":"CL Dai","year":"2017","unstructured":"Dai CL, Tung YC, Liu F, Gong CX, Iqbal K. Tau passive immunization inhibits not only tau but also A\u03b2 pathology. Alzheimers Res Ther. 2017;9:1.","journal-title":"Alzheimers Res Ther"},{"key":"337_CR16","unstructured":"Drummond E, Goni F, Liu S, Prelli F, Scholtzova H, Wisniewski T. Potential novel approaches to understand the pathogenesis and treat Alzheimer\u2019s disease. J Alzheimers Dis. In press."},{"key":"337_CR17","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.1038\/s41598-017-10393-z","volume":"7","author":"F Goni","year":"2017","unstructured":"Goni F, Marta-Ariza M, Peyser D, Herline K, Wisniewski T. Production of monoclonal antibodies to pathologic \u03b2-sheet oligomeric conformers in neurodegenerative diseases. Sci Rep. 2017;7:9881.","journal-title":"Sci Rep"},{"key":"337_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1742-2094-10-150","volume":"10","author":"F Goni","year":"2013","unstructured":"Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta PD, Wisniewski T. Immunomodulation targeting both A\u03b2 and tau pathological conformers ameliorates Alzheimer\u2019s disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation. 2013;10:150.","journal-title":"J Neuroinflammation"},{"key":"337_CR19","doi-asserted-by":"publisher","first-page":"e13391","DOI":"10.1371\/journal.pone.0013391","volume":"5","author":"F Goni","year":"2010","unstructured":"Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer\u2019s disease. PLoS One. 2010;5:e13391.","journal-title":"PLoS One"},{"key":"337_CR20","first-page":"113","volume":"7","author":"KS Kim","year":"1990","unstructured":"Kim KS, Wen GY, Bancher C, Chen CMJ, Sapienza V, Hong H, Wisniewski HM. Detection and quantification of amyloid \u03b2-peptide with 2 monoclonal antibodies. Neurosci Res Comm. 1990;7:113\u201322.","journal-title":"Neurosci Res Comm"},{"key":"337_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jnr.490390607","volume":"39","author":"L Otvos Jr","year":"1994","unstructured":"Otvos Jr L, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669\u201373.","journal-title":"J Neurosci Res"},{"key":"337_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2202-11-130","volume":"11","author":"E Chung","year":"2010","unstructured":"Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer\u2019s disease model mouse. BMC Neurosci. 2010;11:130.","journal-title":"BMC Neurosci"},{"key":"337_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.vaccine.2014.11.035","volume":"33","author":"F Goni","year":"2015","unstructured":"Goni F, Mathiason CK, Yim L, Wong K, Hayes-Klug J, Nalls A, Peyser D, Estevez V, Denkers ND, Xu J, Osborn DA, Miller KV, Warren RJ, Brown DR, Chabalgoity JA, Hoover EA, Wisniewski T. Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine. 2015;33:726\u201333.","journal-title":"Vaccine"},{"key":"337_CR24","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1038\/s41598-017-08604-8","volume":"7","author":"S Liu","year":"2017","unstructured":"Liu S, Park S, Allington G, Prelli F, Sun Y, Mart\u00e1-Ariza M, Scholtzova H, Biswas G, Brown B, Verghese PB, Mehta PD, Kwon YU, Wisniewski T. Targeting apolipoprotein E\/amyloid \u03b2 binding by peptoid CPO_A\u03b217-21 P ameliorates Alzheimer\u2019s disease related pathology and cognitive decline. Sci Rep. 2017;7:8009.","journal-title":"Sci Rep"},{"key":"337_CR25","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"337_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1471-4159.1988.tb01087.x","volume":"51","author":"F Prelli","year":"1988","unstructured":"Prelli F, Casta\u00f1o EM, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer\u2019s disease. J Neurochem. 1988;51:648\u201351.","journal-title":"J Neurochem"},{"key":"337_CR27","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1073\/pnas.91.18.8378","volume":"91","author":"J Naslund","year":"1994","unstructured":"Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, et al. Relative abundance of Alzheimer A\u03b2 amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994;91:8378\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"337_CR28","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectroscopy of purified amyloid \u03b2 protein in Alzheimer\u2019s disease. J Biol Chem. 1992;267:17082\u20136.","journal-title":"J Biol Chem"},{"key":"337_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.neuron.2005.06.030","volume":"47","author":"E McGowan","year":"2005","unstructured":"McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. A\u03b242 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191\u20139.","journal-title":"Neuron"},{"key":"337_CR30","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1074\/jbc.M507892200","volume":"281","author":"S Oddo","year":"2006","unstructured":"Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-\u03b2 (A\u03b2) oligomerization in an in vivo model of Alzheimer disease: a link between A\u03b2 and tau pathology. J Biol Chem. 2006;281:1599\u2013604.","journal-title":"J Biol Chem"},{"key":"337_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"337_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.expneurol.2007.05.005","volume":"206","author":"WA Banks","year":"2007","unstructured":"Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M. Anti-amyloid \u03b2 protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer\u2019s disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol. 2007;206:248\u201356.","journal-title":"Exp Neurol"},{"key":"337_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1515\/CCLM.2003.053","volume":"41","author":"H Reiber","year":"2003","unstructured":"Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, de Almeida Monteiro S, Fredman P, Keir G, Lammers M, Liblau R, Menna-Barreto M, Sa MJ, Seres E, Sindic CJ, Teelken A, Trendelenburg C, Trojano M, van Antwerpen MP, Verbeek MM. Quality assurance for cerebrospinal fluid protein analysis: international consensus by an Internet-based group discussion. Clin Chem Lab Med. 2003;41:331\u20137.","journal-title":"Clin Chem Lab Med"},{"key":"337_CR34","first-page":"101","volume":"2","author":"H Scholtzova","year":"2014","unstructured":"Scholtzova H, Chianchiano P, Pan J, Sun Y, Goni F, Mehta PD, Wisniewski T. Toll-like receptor 9 stimulation for reduction of amyloid \u03b2 and tau Alzheimer\u2019s disease related pathology. Acta Neuropathol Commun. 2014;2:101.","journal-title":"Acta Neuropathol Commun"},{"key":"337_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer\u2019s disease: experimental models and reality. Acta Neuropathol. 2017;133:155\u201375.","journal-title":"Acta Neuropathol"},{"key":"337_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.","journal-title":"Alzheimers Res Ther"},{"key":"337_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3233\/JAD-150136","volume":"47","author":"A Banik","year":"2015","unstructured":"Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, Chen W, Ding Y, Mudher A, Padjen AL, Mukaetova-Ladinska E, Ihara M, Srivastava S, Padma Srivastava MV, Masters CL, Kalaria RN, Anand A. Translation of pre-clinical studies into successful clinical trials for Alzheimer\u2019s disease: what are the roadblocks and how can they be overcome? J Alzheimers Dis. 2015;47:815\u201343.","journal-title":"J Alzheimers Dis"},{"key":"337_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251\u201383.","journal-title":"J Intern Med"},{"key":"337_CR39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000478741","volume":"17","author":"Y Wang","year":"2017","unstructured":"Wang Y, Yan T, Lu H, Yin W, Lin B, Fan W, Zhang X, Fernandez-Funez P. Lessons from anti-amyloid-\u03b2 immunotherapies in Alzheimer disease: aiming at a moving target. Neurodegener Dis. 2017;17:242\u201350.","journal-title":"Neurodegener Dis"},{"key":"337_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14737175.2017.1326819","volume":"17","author":"A Khan","year":"2017","unstructured":"Khan A, Corbett A, Ballard C. Emerging amyloid and tau targeting treatments for Alzheimer\u2019s disease. Expert Rev Neurother. 2017;17:697\u2013711.","journal-title":"Expert Rev Neurother"},{"key":"337_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"337_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta U, Nilson AN, Kayed R. The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy. EBioMedicine. 2016;6:42\u20139.","journal-title":"EBioMedicine"},{"key":"337_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-510X(00)00501-3","volume":"184","author":"H Reiber","year":"2001","unstructured":"Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001;184:101\u201322.","journal-title":"J Neurol Sci"},{"key":"337_CR44","doi-asserted-by":"publisher","first-page":"e28881","DOI":"10.1371\/journal.pone.0028881","volume":"6","author":"G Sarkar","year":"2011","unstructured":"Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, Blahnik A, Hoesley B, Lowe VJ, Poduslo JF, Jenkins RB. A carrier for non-covalent delivery of functional \u03b2-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS One. 2011;6:e28881.","journal-title":"PLoS One"},{"key":"337_CR45","doi-asserted-by":"publisher","first-page":"8490","DOI":"10.1038\/ncomms9490","volume":"6","author":"S Takeda","year":"2015","unstructured":"Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, Nicholls SB, Carlson GA, Pitstick R, Nobuhara CK, Costantino I, Frosch MP, Muller DJ, Irimia D, Hyman BT. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer\u2019s disease brain. Nat Commun. 2015;6:8490.","journal-title":"Nat Commun"},{"key":"337_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fnins.2015.00196","volume":"9","author":"N Maphis","year":"2015","unstructured":"Maphis N, Xu G, Kokiko-Cochran ON, Cardona AE, Ransohoff RM, Lamb BT, Bhaskar K. Loss of tau rescues inflammation-mediated neurodegeneration. Front Neurosci. 2015;9:196.","journal-title":"Front Neurosci"},{"key":"337_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505\u20138.","journal-title":"JAMA Neurol"},{"key":"337_CR48","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis J, Dickson D, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487\u201391.","journal-title":"Science"},{"key":"337_CR49","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J G\u00f6tz","year":"2001","unstructured":"G\u00f6tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A\u03b242 fibrils. Science. 2001;293:1491\u20135.","journal-title":"Science"},{"key":"337_CR50","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ajpath.2017.03.011","volume":"187","author":"RE Bennett","year":"2017","unstructured":"Bennett RE, DeVos SL, Dujardin S, Corjuc B, Gor R, Gonzalez J, Roe AD, Frosch MP, Pitstick R, Carlson GA, Hyman BT. Enhanced tau aggregation in the presence of amyloid \u03b2. Am J Pathol. 2017;187:1601\u201312.","journal-title":"Am J Pathol"},{"key":"337_CR51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry. Brain Pathol. 2000;10:378\u201384.","journal-title":"Brain Pathol"},{"key":"337_CR52","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1212\/WNL.0000000000002480","volume":"86","author":"LR White","year":"2016","unstructured":"White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, Uyehara-Lock JH, Gelber RP, Ross GW, Petrovitch H, Masaki KH, Lim KO, Launer LJ, Montine TJ. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology. 2016;86:1000\u20138.","journal-title":"Neurology"},{"key":"337_CR53","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","volume":"69","author":"JA Schneider","year":"2007","unstructured":"Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197\u2013204.","journal-title":"Neurology"},{"key":"337_CR54","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139:2983\u201393.","journal-title":"Brain"},{"key":"337_CR55","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.biopsych.2017.05.014","volume":"83","author":"AA Pimenova","year":"2018","unstructured":"Pimenova AA, Raj T, Goate AM. Untangling genetic risk for Alzheimer\u2019s disease. Biol Psychiatry. 2018;83:300\u201310.","journal-title":"Biol Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0337-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0337-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T10:45:51Z","timestamp":1660387551000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0337-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0337-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All human tissue-related studies were done according to appropriate ethical standards under a protocol approved by the institutional review board at NYU School of Medicine, Board C (study number i2942). In all cases, written informed consent for research was obtained from the patient or the patient\u2019s legal guardian, and the material used had appropriate ethical approval for use in this project. All patients\u2019 data and samples were coded and handled according to NIH guidelines to protect patients\u2019 identities. All animal procedures were approved by the NYU Institutional Animal Care and Use Committee (protocol 170202-01) and were carried out according to NIH standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"10"}}